BioWorld

March 17, 2008

View Archived Issues

Transition Could Get $130M in Diabetes Deal With Lilly

Transition Therapeutics Inc. could receive up to $137 million in a deal with drug giant Eli Lilly and Co., which will acquire rights to Transition's gastrin-based therapies for diabetes. (BioWorld Today) Read More

Legislation Would Create Path for Follow-on Biologics Work

Read More

T-Cell Gene is Linchpin for Breast Cancer Metastasis

Read More

Investigations Looming in Off-Label Promotion

Read More

Corrections & Clarifications

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More